[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

DK3339321T3 - Modulatorer af myc, fremgangsmåder til anvendelse af samme og fremgangsmåder til at identificere stoffer der modulerer myc - Google Patents

Modulatorer af myc, fremgangsmåder til anvendelse af samme og fremgangsmåder til at identificere stoffer der modulerer myc Download PDF

Info

Publication number
DK3339321T3
DK3339321T3 DK18154875.1T DK18154875T DK3339321T3 DK 3339321 T3 DK3339321 T3 DK 3339321T3 DK 18154875 T DK18154875 T DK 18154875T DK 3339321 T3 DK3339321 T3 DK 3339321T3
Authority
DK
Denmark
Prior art keywords
methods
myc
modulars
same
modulate
Prior art date
Application number
DK18154875.1T
Other languages
English (en)
Inventor
Brian Curtis Turner
Yosef Refaeli
Original Assignee
Taiga Biotechnologies Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Taiga Biotechnologies Inc filed Critical Taiga Biotechnologies Inc
Application granted granted Critical
Publication of DK3339321T3 publication Critical patent/DK3339321T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A61P31/06—Antibacterial agents for tuberculosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/001—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof by chemical synthesis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/82—Translation products from oncogenes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/20—Fusion polypeptide containing a tag with affinity for a non-protein ligand
    • C07K2319/21—Fusion polypeptide containing a tag with affinity for a non-protein ligand containing a His-tag
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • Virology (AREA)
  • Immunology (AREA)
  • Communicable Diseases (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Pulmonology (AREA)
  • Rheumatology (AREA)
  • Epidemiology (AREA)
  • Toxicology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Zoology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Biotechnology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
DK18154875.1T 2008-08-28 2009-08-28 Modulatorer af myc, fremgangsmåder til anvendelse af samme og fremgangsmåder til at identificere stoffer der modulerer myc DK3339321T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US9270808P 2008-08-28 2008-08-28
EP15175802.6A EP2966084B1 (en) 2008-08-28 2009-08-28 Modulators of myc, methods of using the same and methods of identifying agents that modulate myc

Publications (1)

Publication Number Publication Date
DK3339321T3 true DK3339321T3 (da) 2021-06-21

Family

ID=41722332

Family Applications (3)

Application Number Title Priority Date Filing Date
DK15175802.6T DK2966084T3 (da) 2008-08-28 2009-08-28 Modulatorer af myc, fremgangsmåder til anvendelse af samme og fremgangsmåder til identificering af stoffer, der modulerer myc
DK18154875.1T DK3339321T3 (da) 2008-08-28 2009-08-28 Modulatorer af myc, fremgangsmåder til anvendelse af samme og fremgangsmåder til at identificere stoffer der modulerer myc
DK09810692.5T DK2318435T3 (da) 2008-08-28 2009-08-28 Modulatorer af MYC, fremgangsmåder til anvendelse af samme og fremgangsmåder til identificering af midler, som modulerer MYC

Family Applications Before (1)

Application Number Title Priority Date Filing Date
DK15175802.6T DK2966084T3 (da) 2008-08-28 2009-08-28 Modulatorer af myc, fremgangsmåder til anvendelse af samme og fremgangsmåder til identificering af stoffer, der modulerer myc

Family Applications After (1)

Application Number Title Priority Date Filing Date
DK09810692.5T DK2318435T3 (da) 2008-08-28 2009-08-28 Modulatorer af MYC, fremgangsmåder til anvendelse af samme og fremgangsmåder til identificering af midler, som modulerer MYC

Country Status (11)

Country Link
US (7) US8784825B2 (da)
EP (4) EP3339321B1 (da)
JP (5) JP5812861B2 (da)
CN (2) CN102089323B (da)
AU (1) AU2009285547B2 (da)
CA (1) CA2735522C (da)
DK (3) DK2966084T3 (da)
ES (3) ES2561599T3 (da)
IL (6) IL301475A (da)
SG (1) SG193831A1 (da)
WO (1) WO2010025421A2 (da)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1942739B1 (en) 2005-10-18 2010-12-08 National Jewish Health Conditionally immortalized long-term adult stem cells and methods of making and using such cells
KR20140092232A (ko) * 2007-03-13 2014-07-23 내셔날 쥬이쉬 헬스 항체의 제조 방법
AU2009246876B2 (en) * 2008-05-16 2015-04-02 Htyr Acquisition Llc Antibodies and processes for preparing the same
CA2731767C (en) 2008-07-21 2016-12-06 Taiga Biotechnologies, Inc. Differentiated anucleated cells and method for preparing the same
SG193831A1 (en) 2008-08-28 2013-10-30 Taiga Biotechnologies Inc Modulators of myc, methods of using the same, and methods of identifying agents that modulate myc
EP2868325B1 (en) * 2012-07-02 2017-11-01 Sumitomo Dainippon Pharma Co., Ltd. Transdermal cancer antigen peptide preparation
AU2013292330B2 (en) 2012-07-20 2018-07-12 Htyr Acquisition Llc Enhanced reconstitution and autoreconstitution of the hematopoietic compartment
US10272115B2 (en) 2013-03-11 2019-04-30 Taiga Biotechnologies, Inc. Production and use of red blood cells
US9365825B2 (en) 2013-03-11 2016-06-14 Taiga Biotechnologies, Inc. Expansion of adult stem cells in vitro
AU2014231816B2 (en) 2013-03-12 2016-11-03 Sumitomo Dainippon Pharma Co., Ltd. Liquid aqueous composition
WO2016014794A1 (en) 2014-07-25 2016-01-28 Sangamo Biosciences, Inc. Methods and compositions for modulating nuclease-mediated genome engineering in hematopoietic stem cells
ES2886012T3 (es) 2014-09-16 2021-12-16 Sangamo Therapeutics Inc Métodos y composiciones para la ingeniería y corrección de genomas mediadas por nucleasas en células madre hematopoyéticas
US10583156B2 (en) 2016-12-02 2020-03-10 Taiga Biotechnologies, Inc. Nanoparticle formulations
US10149898B2 (en) * 2017-08-03 2018-12-11 Taiga Biotechnologies, Inc. Methods and compositions for the treatment of melanoma
AU2018308982A1 (en) * 2017-08-03 2020-02-13 Taiga Biotechnologies, Inc. Methods and compositions for the treatment of cancer
CA3035209A1 (en) * 2017-08-03 2019-02-07 Taiga Biotechnologies, Inc. Methods and compositions for the treatment of melanoma
SG11202111081XA (en) * 2019-04-08 2021-11-29 Taiga Biotechnologies Inc Compositions and methods for the cryopreservation of immune cells
CN114072166A (zh) * 2019-05-14 2022-02-18 泰加生物工艺学公司 用于治疗t细胞耗竭的组合物和方法
JP7197538B2 (ja) * 2020-07-03 2022-12-27 タイガ バイオテクノロジーズ，インク． メラノーマの処置のための方法および組成物
WO2023147486A1 (en) 2022-01-28 2023-08-03 Iovance Biotherapeutics, Inc. Tumor infiltrating lymphocytes engineered to express payloads
WO2025101484A1 (en) 2023-11-06 2025-05-15 Iovance Biotherapeutics, Inc. Treatment of endometrial cancers with tumor infiltrating lymphocyte therapies

Family Cites Families (135)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ZA811368B (en) 1980-03-24 1982-04-28 Genentech Inc Bacterial polypedtide expression employing tryptophan promoter-operator
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
WO1986003780A1 (en) 1984-12-21 1986-07-03 Techniclone Research Partners I Method for electrically immortalizing lymphoid cells
DE3531430A1 (de) 1985-09-03 1987-03-05 Biotest Pharma Gmbh Verfahren zur gewinnung von komponenten aus einer fluessigkeit mit in raeumlich getrennten bereichen vorliegenden komponenten
US4963489A (en) 1987-04-14 1990-10-16 Marrow-Tech, Inc. Three-dimensional cell and tissue culture system
US4900322A (en) 1986-09-22 1990-02-13 Adams James D Blood component pooling valve and kit
US5476996A (en) 1988-06-14 1995-12-19 Lidak Pharmaceuticals Human immune system in non-human animal
US5399493A (en) 1989-06-15 1995-03-21 The Regents Of The University Of Michigan Methods and compositions for the optimization of human hematopoietic progenitor cell cultures
US5804604A (en) 1989-12-21 1998-09-08 Biogen, Inc. Tat-derived transport polypeptides and fusion proteins
US5652122A (en) 1989-12-21 1997-07-29 Frankel; Alan Nucleic acids encoding and methods of making tat-derived transport polypeptides
US5849288A (en) 1990-01-15 1998-12-15 Yeda Research And Development Co. Ltd. Method for production of monoclonal antibodies in chimeric mice or rats having xenogeneic antibody-producing cells
US6255458B1 (en) 1990-08-29 2001-07-03 Genpharm International High affinity human antibodies and human antibodies against digoxin
NZ241855A (en) 1991-03-07 1994-04-27 Gen Hospital Corp Use of therapeutic cells to obtain cellular response to infection, tumours or autoimmune-generated cells, cells with chimaeric receptors (with binding component and destruction signal), dna encoding the receptor, vectors and antibodies to receptor
US6753162B1 (en) 1991-03-07 2004-06-22 The General Hospital Corporation Targeted cytolysis of HIV-infected cells by chimeric CD4 receptor-bearing cells
US5843728A (en) 1991-03-07 1998-12-01 The General Hospital Corporation Redirection of cellular immunity by receptor chimeras
US5851828A (en) 1991-03-07 1998-12-22 The General Hospital Corporation Targeted cytolysis of HIV-infected cells by chimeric CD4 receptor-bearing cells
US5912170A (en) 1991-03-07 1999-06-15 The General Hospital Corporation Redirection of cellular immunity by protein-tyrosine kinase chimeras
US6004811A (en) 1991-03-07 1999-12-21 The Massachussetts General Hospital Redirection of cellular immunity by protein tyrosine kinase chimeras
AU781922B2 (en) 1991-12-17 2005-06-23 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5289858A (en) 1991-12-18 1994-03-01 Abbott Laboratories System for accommodating withdrawal of liquid from a bulk supply
US8211422B2 (en) 1992-03-18 2012-07-03 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Chimeric receptor genes and cells transformed therewith
JP2702285B2 (ja) 1992-08-21 1998-01-21 バイオジェン，インコーポレイテッド Ｔａｔ由来の輸送ポリペプチド
US5580760A (en) * 1993-02-22 1996-12-03 The United States Of America As Represented By The Department Of Health And Human Services FUSE binding protein and cDNA therefor
WO1995003402A1 (en) 1993-07-22 1995-02-02 Merck & Co., Inc. EXPRESSION OF HUMAN INTERLEUKIN-1β IN A TRANSGENIC ANIMAL
US5599705A (en) 1993-11-16 1997-02-04 Cameron; Robert B. In vitro method for producing differentiated universally compatible mature human blood cells
ES2204944T3 (es) 1994-03-03 2004-05-01 Alexion Pharmaceuticals, Inc. Genes y proteinas de fusion inhibidores del complemento terminal.
US5827642A (en) 1994-08-31 1998-10-27 Fred Hutchinson Cancer Research Center Rapid expansion method ("REM") for in vitro propagation of T lymphocytes
US6713247B1 (en) 1996-09-03 2004-03-30 Signal Pharmaceuticials, Inc. Human CNS cell lines and methods of use therefor
EP0975370B9 (en) 1997-05-21 2004-11-03 The Board Of Trustees Of The Leland Stanford Junior University Composition and method for enhancing transport across biological membranes
EP0893493A3 (de) 1997-07-21 2002-12-04 Aventis Pharma Deutschland GmbH Genetisch veränderte Zellen und deren Verwendung in der Prophylaxe oder Therapie von Erkrankungen
GB9720585D0 (en) 1997-09-26 1997-11-26 Smithkline Beecham Biolog Vaccine
CA2314267A1 (en) 1997-12-10 1999-06-17 Washington University Anti-pathogen system and methods of use thereof
JP4271857B2 (ja) 1998-04-08 2009-06-03 塩野義製薬株式会社 破骨細胞前駆細胞の単離並びにその破骨細胞への分化誘導法
US6835567B1 (en) 1998-04-14 2004-12-28 Signal Pharmaceuticals, Inc. PNS cell lines and methods of use therefor
US6451558B1 (en) 1998-08-03 2002-09-17 Novartis Ag Genes in the control of hematopoiesis
US6913925B1 (en) 1998-08-12 2005-07-05 Signal Pharmaceuticals Llc Human mesencephalon cell lines and methods of use therefor
WO2000062067A1 (en) 1999-02-28 2000-10-19 Washington University Novel transduction molecules and methods for using same
WO2000059540A1 (en) 1999-04-05 2000-10-12 Biocrystal Ltd. Assay kits and methods for immune complex-mediated activation involving shed antigens
US6451601B1 (en) 1999-04-12 2002-09-17 Modex Therapeutiques, S.A. Transiently immortalized cells for use in gene therapy
WO2000061617A2 (en) 1999-04-12 2000-10-19 Modex Therapeutiques, S.A. Transiently immortalized cells for use in gene therapy
US6358739B1 (en) 1999-04-12 2002-03-19 Modex Therapeutiques, S.A. Transiently immortalized cells
US7135287B1 (en) 1999-10-02 2006-11-14 Biosite, Inc. Human antibodies
US7311920B1 (en) 1999-10-08 2007-12-25 University Of Maryland Biotechnology Institute Virus coat protein/receptor chimeras and methods of use
AU1482101A (en) 1999-11-10 2001-06-06 Rigel Pharmaceuticals, Inc. Methods and compositions comprising renilla gfp
EP1103615A1 (en) 1999-11-25 2001-05-30 Universite De Geneve Vectors capable of immortalizing non-dividing cells and cells immortalized with said vectors
US20010049393A1 (en) * 1999-12-07 2001-12-06 Whitehead Institute For Biomedical Research Methods for defining MYC target genes and uses thereof
EP1285577A4 (en) 2000-05-15 2007-05-09 Sonoko Habu CHIMERIC MOUSE HAVING IMMUNITY CREATED BY USE OF HUMAN CD34 POSITIVE CELLS AND USE THEREOF
US20020155127A1 (en) 2000-06-02 2002-10-24 Danher Wang Genetic vaccine against human immunodeficiency virus
US20030072794A1 (en) 2000-06-09 2003-04-17 Teni Boulikas Encapsulation of plasmid DNA (lipogenes™) and therapeutic agents with nuclear localization signal/fusogenic peptide conjugates into targeted liposome complexes
US20070248618A1 (en) * 2004-03-16 2007-10-25 Cohen David I Tat-Based vaccine Compositions and Methods of Making and Using Same
DE60138404D1 (de) 2000-09-25 2009-05-28 Baylor College Medicine Verbessertes system zur regulation der transgenexpression
EP1330551A2 (en) 2000-10-30 2003-07-30 Kalobios, Inc. Affinity maturation by competitive selection
ES2386884T3 (es) 2000-11-01 2012-09-04 The Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Vectores de expresión capaces de inducir respuesta inmunomejorada y métodos para usarlos
US7145055B2 (en) 2000-12-01 2006-12-05 Central Institute For Experimental Animals Method of producing a mouse suitable for the engraftment, differentiation and proliferation of heterologous cells, mouse produced by this method and use of the mouse
WO2002057436A2 (en) 2001-01-19 2002-07-25 Gendel Limited Red blood cell from a transgenic animal as vehicle for polypeptide delivery
US7033744B2 (en) 2001-03-16 2006-04-25 Naoya Kobayashi Method for proliferating a liver cell, a liver cell obtained thereby, and use thereof
IL160359A0 (en) 2001-08-31 2004-07-25 Avidex Ltd Soluble t cell receptor
CN100506978C (zh) 2001-09-21 2009-07-01 中国人民解放军军事医学科学院野战输血研究所 一种新的造血干/祖细胞的富集方法及其体外定向诱导分化
GB0124391D0 (en) 2001-10-11 2001-11-28 Gene Expression Technologies L Control of gene expression
US20030147887A1 (en) 2001-11-02 2003-08-07 Shen-Wu Wang B-cell lymphoma specific antigen for use in diagnosis and treatment of B-cell malignancies
US7745140B2 (en) 2002-01-03 2010-06-29 The Trustees Of The University Of Pennsylvania Activation and expansion of T-cells using an engineered multivalent signaling platform as a research tool
US7670781B2 (en) 2002-01-03 2010-03-02 The Trustees Of The University Of Pennsylvania Activation and expansion of T-cells using an agent that provides a primary activation signal and another agent that provides a co-stimulatory signal
JP4632664B2 (ja) 2002-02-13 2011-02-16 デューク ユニバーシティ 非ペプチド結合ストレス応答性ポリペプチドによる免疫応答の調節
CN1240439C (zh) 2002-03-28 2006-02-08 南京凯基生物科技发展有限公司 肿瘤基因开关药物
US7211191B2 (en) 2004-09-30 2007-05-01 Thermogenesis Corp. Blood component separation method and apparatus
JP2005523012A (ja) 2002-04-16 2005-08-04 デイナ−ファーバー キャンサー インスティチュート，インコーポレイテッド 癌モデル
GB2387599B (en) 2002-04-17 2005-08-10 Jason Peter Brown Methods for producing antibodies
AU2003228962A1 (en) 2002-05-10 2003-11-11 New Century Pharmaceuticals, Inc. Ferritin fusion proteins for use in vaccines and other applications
PT1652857E (pt) 2002-05-16 2008-12-12 Bavarian Nordic As Proteína de fusão de proteínas reguladoras/acessórias do hiv
CA2497552C (en) 2002-09-06 2014-05-27 The Government Of The United States Of America, Represented By The Secretary, Department Of Health And Human Services Immunotherapy with in vitro-selected antigen-specific lymphocytes after nonmyeloablative lymphodepleting chemotherapy
JP4436319B2 (ja) 2002-10-09 2010-03-24 メディジーン リミテッド 単鎖組換えｔ細胞レセプター
EP1408114B1 (de) * 2002-10-11 2007-01-03 Imvision GmbH Moduläre Antigen-Transporter Moleküle (MAT-Moleküle) zur Modulierung von Immunreaktionen, zugehörige Konstrukte, Verfahren und Verwendungen
WO2004035535A2 (en) 2002-10-15 2004-04-29 Yeda Research And Development Co. Ltd. Erythrocyte differentiation factor, gene encoding same, and methods of use thereof
NZ539226A (en) 2002-11-09 2008-09-26 Medigene Ltd T cell receptor display
AU2003288433B2 (en) 2002-12-05 2009-06-25 Imperial College Innovations Limited Control of apoptosis using a complex of an oligonucleotide and a regulatory peptide
JP4509999B2 (ja) 2003-02-17 2010-07-21 ブルクハルト，ペーター 医薬送達及び抗原提示システムとしてのペプチドナノ粒子
GB0304068D0 (en) 2003-02-22 2003-03-26 Avidex Ltd Substances
WO2004084805A2 (en) 2003-03-19 2004-10-07 The J. David Gladstone Institutes Acetylated tat polypeptides and methods of use thereof
JP2006524991A (ja) 2003-05-08 2006-11-09 エクサイト セラピーズ インコーポレーティッド 抗原特異的ｔ細胞の作製および単離の方法
WO2005014785A2 (en) 2003-06-18 2005-02-17 The George Washington University Conditionally-immortalized hematopoietic progenitor cell lines
CA2529752A1 (en) 2003-06-20 2005-09-15 The Regents Of The University Of California Polypeptide transduction and fusogenic peptides
IL161903A0 (en) 2003-07-17 2005-11-20 Gamida Cell Ltd Ex vivo progenitor and stem cell expansion for usein the treatment of disease of endodermally- deri ved organs
US7842294B2 (en) 2003-11-19 2010-11-30 Survac Aps Proteins belonging to the Bcl-2 family and fragments thereof, and their use in cancer patients
US7705049B2 (en) 2004-01-21 2010-04-27 New York University Methods for treating non-melanoma cancers with PABA
JP2005232148A (ja) 2004-02-03 2005-09-02 Technion Research & Development Foundation Ltd 神経保護剤としてプロパルギルアミンの使用
WO2005113595A2 (en) 2004-05-19 2005-12-01 Avidex Ltd High affinity ny-eso t cell receptor
ATE408684T1 (de) 2004-05-19 2008-10-15 Medigene Ltd Verfahren zur verbesserung von t-zellrezeptoren
EP1791865B1 (en) 2004-06-29 2010-07-28 Immunocore Ltd. Cells expressing a modified t cell receptor
WO2006137836A2 (en) 2004-08-17 2006-12-28 Research Development Foundation Bacterial vector systems
GB0420963D0 (en) 2004-09-21 2004-10-20 Reneuron Ltd Hepatocyte
US7767453B2 (en) 2004-10-20 2010-08-03 Whitehead Institute For Biomedical Research Cultured hematopoietic stem cells and method for expansion and analysis thereof
WO2007067183A1 (en) 2005-12-09 2007-06-14 The Regents Of The University Of California Derivation of unlimited quantities of neutrophils or monocyte/dendritic cells
US20060156422A1 (en) 2005-01-10 2006-07-13 Medical Research Council Methods and compositions for the generation of antibodies
WO2006104978A2 (en) 2005-03-25 2006-10-05 Curagen Corporation Antibodies against the tenascin major antigens
EP1876894A1 (en) 2005-04-26 2008-01-16 The Board of Trustees of the University of Illinois Nucleoside compounds and methods of use thereof
EP1885754B1 (en) 2005-05-25 2011-02-09 Immunocore Ltd. T cell receptors which specifically bind to vygfvracl-hla-a24
JP5276982B2 (ja) 2005-08-26 2013-08-28 ボード オブ トラスティーズ オブ ザ レランド スタンフォード ジュニア ユニバーシティ オキシトシンの投与による頭痛の処置のための方法
US20070047583A1 (en) 2005-08-29 2007-03-01 Siemens Aktiengesellschaft Method for using a short address in a packet header
EP1942739B1 (en) 2005-10-18 2010-12-08 National Jewish Health Conditionally immortalized long-term adult stem cells and methods of making and using such cells
US7582745B2 (en) 2005-11-04 2009-09-01 Alnylam Pharmaceuticals, Inc. Compositions and methods for inhibiting expression of Nav1.8 gene
EP1792627A1 (en) 2005-12-05 2007-06-06 ImVisioN AG Modulation of the immune response by administration of intralymphatic transduction allergen (ITAG-)-molecules
US20080070256A1 (en) 2006-07-26 2008-03-20 National Jewish Medical And Research Center Non-Human Animal Models for B-cell Non-Hodgkin's Lymphoma and Uses Thereof
US8088379B2 (en) 2006-09-26 2012-01-03 The United States Of America As Represented By The Department Of Health And Human Services Modified T cell receptors and related materials and methods
EP2087000A2 (en) 2006-09-29 2009-08-12 Immunocore Ltd. T cell therapies
KR20140092232A (ko) 2007-03-13 2014-07-23 내셔날 쥬이쉬 헬스 항체의 제조 방법
WO2009059304A2 (en) 2007-11-02 2009-05-07 Taiga Biotechnologies, Inc. Compounds for treating abnormal cellular proliferation
SG10201808863UA (en) 2008-03-17 2018-11-29 Scripps Research Inst Combined chemical and genetic approaches for generation of induced pluripotent stem cells
AU2009246876B2 (en) * 2008-05-16 2015-04-02 Htyr Acquisition Llc Antibodies and processes for preparing the same
EP2304035A2 (en) 2008-06-13 2011-04-06 Life & Brain GmbH Fusion protein and use thereof
CA2731767C (en) 2008-07-21 2016-12-06 Taiga Biotechnologies, Inc. Differentiated anucleated cells and method for preparing the same
SG193831A1 (en) 2008-08-28 2013-10-30 Taiga Biotechnologies Inc Modulators of myc, methods of using the same, and methods of identifying agents that modulate myc
EP3824884A1 (en) 2008-11-06 2021-05-26 Indiana University Research and Technology Corporation Materials and methods to enhance hematopoietic stem cells engraftment procedures
WO2010058023A1 (en) 2008-11-24 2010-05-27 Helmholtz Zentrum München Deutsches Forschungszentrum Für Gesundheit Und Umwelt Gmbh High affinity t cell receptor and use thereof
WO2011100477A2 (en) 2010-02-10 2011-08-18 Taiga Biotechnologies, Inc. Antibodies and processes for preparing the same
US20120107317A1 (en) 2010-10-27 2012-05-03 The University Of Hong Kong Use of cytoplasmic c-myc for regulating immune responses
US20120244133A1 (en) 2011-03-22 2012-09-27 The United States of America, as represented by the Secretary, Department of Health and Methods of growing tumor infiltrating lymphocytes in gas-permeable containers
PT3392270T (pt) 2011-09-15 2020-11-24 Us Health Recetores de células t que reconhecem mage restrito a hlaa1 ou hla-cw7
CA2849378A1 (en) 2011-09-21 2013-03-28 Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd. Nano delivery systems for sirna
EP2844743B1 (en) 2012-05-03 2021-01-13 Fred Hutchinson Cancer Research Center Enhanced affinity t cell receptors and methods for making the same
MX2014014196A (es) 2012-05-23 2015-08-14 Univ Ohio State Composiciones de nanoparticulas de albumina recubiertas con lipido y metodos de preparacion y metodo de uso de las mismas.
DE102012209673A1 (de) 2012-06-08 2013-12-24 Artcline Gmbh Verfahren zum Herstellen einer Leukozytenpräparation und Leukozytenpräparation
AU2013292330B2 (en) 2012-07-20 2018-07-12 Htyr Acquisition Llc Enhanced reconstitution and autoreconstitution of the hematopoietic compartment
CA2880098A1 (en) 2012-07-27 2014-01-30 The Board Of Trustees Of The University Of Illinois Engineering t-cell receptors
US20140109246A1 (en) 2012-09-24 2014-04-17 The Regents Of The University Of Colorado, A Body Corporate Methods of generating xenochimaeric mice with tumor and hematopoietic system from the same heterologous species
GB2508414A (en) 2012-11-30 2014-06-04 Max Delbrueck Centrum Tumour specific T cell receptors (TCRs)
CN105163745B (zh) 2013-03-01 2020-06-12 美国卫生和人力服务部 从外周血中产生肿瘤反应性t细胞富集群的方法
EP2961415B1 (en) 2013-03-01 2021-01-06 The United States of America, as represented by The Secretary, Department of Health and Human Services Methods of producing enriched populations of tumor-reactive t cells from tumor
US9365825B2 (en) 2013-03-11 2016-06-14 Taiga Biotechnologies, Inc. Expansion of adult stem cells in vitro
US10272115B2 (en) 2013-03-11 2019-04-30 Taiga Biotechnologies, Inc. Production and use of red blood cells
EP3134515B1 (en) 2014-04-24 2019-03-27 Board of Regents, The University of Texas System Application of induced pluripotent stem cells to generate adoptive cell therapy products
WO2016105542A2 (en) 2014-12-24 2016-06-30 Neximmune, Inc Nanoparticle compositions and methods for immunotherapy
PE20181068A1 (es) 2015-10-02 2018-07-04 Dana Farber Cancer Inst Inc Terapia de combinacion de inhibidores de bromodominios y bloqueo de puntos de control
CA3011087A1 (en) 2016-01-15 2017-07-20 Berkeley Lights, Inc. Methods of producing patient-specific anti-cancer therapeutics and methods of treatment therefor
WO2018104909A2 (en) 2016-12-09 2018-06-14 St. Jude Children's Research Hospital Dna methylation profiling for t-cell immunotherapy
US10149898B2 (en) 2017-08-03 2018-12-11 Taiga Biotechnologies, Inc. Methods and compositions for the treatment of melanoma

Also Published As

Publication number Publication date
CA2735522A1 (en) 2010-03-04
EP2966084B1 (en) 2018-04-25
IL276146B1 (en) 2023-04-01
IL301475A (en) 2023-05-01
HK1159643A1 (zh) 2012-08-03
JP6484293B2 (ja) 2019-03-13
EP3916010A1 (en) 2021-12-01
AU2009285547A1 (en) 2010-03-04
IL264254B (en) 2020-08-31
ES2879225T3 (es) 2021-11-22
IL232432A0 (en) 2014-06-30
EP2966084A1 (en) 2016-01-13
US20240156957A1 (en) 2024-05-16
DK2318435T3 (da) 2016-02-29
EP3339321B1 (en) 2021-04-28
JP2015147789A (ja) 2015-08-20
JP2017197567A (ja) 2017-11-02
HK1257269A1 (en) 2019-10-18
IL232432A (en) 2017-01-31
JP6817353B2 (ja) 2021-01-20
CN102089323A (zh) 2011-06-08
DK2966084T3 (da) 2018-08-06
EP2318435A4 (en) 2011-08-10
IL249700B (en) 2019-02-28
JP2019116481A (ja) 2019-07-18
US20220362377A1 (en) 2022-11-17
IL276146A (en) 2020-09-30
IL209968A0 (en) 2011-02-28
IL209968A (en) 2014-11-30
CN104353066B (zh) 2017-05-10
US8828723B2 (en) 2014-09-09
US20130177586A1 (en) 2013-07-11
ES2561599T3 (es) 2016-02-29
JP7208965B2 (ja) 2023-01-19
IL276146B2 (en) 2023-08-01
JP2012501347A (ja) 2012-01-19
CN104353066A (zh) 2015-02-18
HK1219491A1 (en) 2017-04-07
EP2318435A2 (en) 2011-05-11
CA2735522C (en) 2017-04-18
US9775897B2 (en) 2017-10-03
US8784825B2 (en) 2014-07-22
WO2010025421A2 (en) 2010-03-04
WO2010025421A3 (en) 2010-08-19
JP2021073184A (ja) 2021-05-13
US20200215188A1 (en) 2020-07-09
SG193831A1 (en) 2013-10-30
JP6167130B2 (ja) 2017-07-19
US20140356392A1 (en) 2014-12-04
US20100055129A1 (en) 2010-03-04
US11369678B2 (en) 2022-06-28
IL264254A (en) 2019-02-28
JP5812861B2 (ja) 2015-11-17
EP2318435B1 (en) 2015-12-23
ES2681478T3 (es) 2018-09-13
CN102089323B (zh) 2015-01-21
IL249700A0 (en) 2017-02-28
US10556006B2 (en) 2020-02-11
AU2009285547B2 (en) 2012-05-31
EP3339321A1 (en) 2018-06-27
US20180092972A1 (en) 2018-04-05

Similar Documents

Publication Publication Date Title
DK3339321T3 (da) Modulatorer af myc, fremgangsmåder til anvendelse af samme og fremgangsmåder til at identificere stoffer der modulerer myc
DK2270818T3 (da) Polyelektrolyt og fremgangsmåde til fremstilling af polyelektrolytten
DK2518655T3 (da) Anordning og fremgangsmåde til forebyggelse af hypoglykæmi
DK2376519T3 (da) TGR5-modulatorer og fremgangsmåde til anvendelse deraf
DK2300808T3 (da) Systemer og fremgangsmåder til billeddannelse ved anvendelse af absorption
BRPI0919575A2 (pt) método, e, composição
DK3222615T3 (da) Psma-bindende stoffer og anvendelser deraf
BRPI0920406A2 (pt) dispositivos de terminação e métodos relacionados.
BRPI0809573A8 (pt) composição, e, método
FI20075978A0 (fi) Järjestely ja menetelmä
BRPI0814466A2 (pt) Método.
DK2188336T3 (da) Sammensætning omfattende et eller flere hydrofobt modificerede polyacrylamider og fremgangsmåde til anvendelse af sammensætningen
BRPI0910723A2 (pt) aparelho e método de frenagem.
BRPI0814467A2 (pt) Método, e, biocombustível
BRPI0915433A2 (pt) método, e, dispositivo.
BRPI0823277A2 (pt) Composição, e , método
NO20082795L (no) Blandeapparat og framgangsmate ved bruk av samme
DK2282209T3 (da) Fremgangsmåde til markering af sukkerkæder
DK2222314T3 (da) Anvendelser og midler til opnåelse af bronchorelaxation
DK2252312T3 (da) Fremgangsmåder til forebyggelse eller behandling af insulinresistens
DK3130367T3 (da) System til vurdering af insulinfølsomhed
DK2195548T3 (da) Leje, og fremgangsmåde og håndtering af lejet
BRPI0814167A2 (pt) Composição, e, método
DK2386133T3 (da) Lag til en halv indsat og en halv indsats
BRPI0923059A2 (pt) escareador e placas de lâminas.